Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors - Yahoo Finance

1 year ago 50

, /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) contiguous announced the assignment of John Tsai, M.D., to its committee of directors. Dr. Tsai, who was President, Global Drug Development and Chief Medical Officer astatine Novartis AG from 2018 to 2022, brings much than 20 years of cause improvement and aesculapian affairs acquisition successful planetary pharmaceutical companies to Blueprint Medicines.

"John's wide and heavy acquisition successful managing ample pipelines and divers portfolios for planetary pharmaceutical companies volition marque him a invaluable Board subordinate arsenic we advancement aggregate best-in-class objective improvement programs successful broad, established therapeutic areas," said Kate Haviland, Chief Executive Officer. "We precise overmuch look guardant to the position John volition bring arsenic we proceed to beforehand innovative precision medicine therapeutics that alteration the lives of patients with genomically defined diseases."

"Blueprint Medicines' occurrence to day is awesome and the institution has a clear, breathtaking way to execute its 2027 vision," said Dr. Tsai. "I look guardant to leveraging my acquisition and contributing to the wealthiness of cognition wrong Blueprint arsenic we enactment to present much transformational medicines and interaction much patients' lives."

In addition, the institution announced that George D. Demetri, M.D., FASCO, has retired from the Board of Directors and volition beryllium joining its Scientific Advisory Board. Dr. Demetri had served arsenic a subordinate of Blueprint's committee of directors since December 2014.

"George has been an integral subordinate of our Board since the aboriginal days of Blueprint and helped to usher the institution done important milestones, including our archetypal nationalist offering, archetypal objective programs and respective regulatory approvals," said Ms. Haviland. "We are grateful for his enactment during the company's astir formative stages and that helium volition proceed to enactment the company's adjacent phases arsenic portion of our Scientific Advisory Board."

Dr. Tsai joins the Board of Blueprint Medicines with much than 20 years of acquisition successful bringing innovative therapies to marketplace crossed geographies and therapeutic areas. Most recently, arsenic President, Global Drug Development and Chief Medical Officer astatine Novartis AG, Dr. Tsai led the company's improvement portfolio spanning 160 caller projects and 500 objective trials arsenic good arsenic the squad that secured planetary approvals for 15 caller medicines including treatments utilizing cistron therapy, compartment therapies, and caller precocious platforms. Prior to joining Novartis successful 2018, Dr. Tsai served arsenic Chief Medical Officer and Senior Vice President of Global Medical Affairs astatine Amgen Inc. and spent 11 years astatine Bristol-Myers Squibb Company. During his tenure astatine Bristol-Myers Squibb, Dr. Tsai held positions of expanding work wrong the Medical and Drug Development organizations, including Head of Late Phase Development and Oncology Development Leader, Head of Worldwide Medical Affairs, Chief Medical Officer Europe, Head of U.S. Medical, and Vice-President, Cardiovascular and Metabolics Disease Area. Earlier successful his career, Dr. Tsai held cause improvement roles astatine Pfizer Inc. and manufacturing roles astatine General Electric Company. Dr. Tsai received a B.S.E.E. successful Electrical Engineering from Washington University successful St. Louis and an M.D. from University of Louisville School of Medicine.

About Blueprint Medicines

Blueprint Medicines is simply a planetary precision therapy institution that invents life-changing therapies for radical with crab and humor disorders. Applying an attack that is some precise and agile, we make medicines that selectively people familial drivers, with the extremity of staying 1 measurement up crossed stages of disease. Since 2011, we person leveraged our probe platform, including expertise successful molecular targeting and world-class cause plan capabilities, to rapidly and reproducibly construe subject into a wide pipeline of precision therapies. Today, we are delivering approved medicines straight to patients successful the United States and Europe, and we are globally advancing aggregate programs for systemic mastocytosis, lung crab and different genomically defined cancers, and crab immunotherapy. For much information, sojourn www.BlueprintMedicines.com and travel america connected Twitter (@BlueprintMeds) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This property merchandise contains forward-looking statements wrong the meaning of the Private Securities Litigation Reform Act of 1995, arsenic amended, including, without limitation, statements regarding Blueprint Medicines' strategy, goals and anticipated milestones, concern plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and akin expressions are intended to place forward-looking statements, though not each forward-looking statements incorporate these identifying words. Any forward-looking statements successful this study are based connected management's existent expectations and beliefs and are taxable to a fig of risks, uncertainties and important factors that whitethorn origin existent events oregon results to disagree materially from those expressed oregon implied by immoderate forward-looking statements contained successful this report, including, without limitation, risks and uncertainties related to the interaction of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned probe and find activities, quality to behaviour ongoing and planned objective trials, objective proviso of existent oregon aboriginal cause candidates, commercialized proviso of existent oregon aboriginal approved products, and launching, selling and selling existent oregon aboriginal approved products; Blueprint Medicines' quality and plans successful continuing to found and grow a commercialized infrastructure, and successfully launching, selling and selling existent oregon aboriginal approved products; Blueprint Medicines' quality to successfully grow the approved indications for AYVAKIT/AYVAKYT and GAVRETO oregon get selling support for AYVAKIT/AYVAKYT successful further geographies successful the future; the hold of immoderate existent oregon planned objective trials oregon the improvement of Blueprint Medicines' existent oregon aboriginal cause candidates; Blueprint Medicines' advancement of aggregate early-stage efforts; Blueprint Medicines' quality to successfully show the information and efficacy of its cause candidates and summation support of its cause candidates connected a timely basis, if astatine all; the preclinical and objective results for Blueprint Medicines' cause candidates, which whitethorn not enactment further improvement of specified cause candidates either arsenic monotherapies oregon successful operation with different agents oregon whitethorn interaction the anticipated timing of information oregon regulatory submissions; the timing of the initiation of objective trials and proceedings cohorts astatine objective proceedings sites and diligent enrollment rates; actions of regulatory agencies, which whitethorn impact the initiation, timing and advancement of objective trials; Blueprint Medicines' quality to obtain, support and enforce patent and different intelligence spot extortion for AYVAKIT/AYVAKYT, GAVRETO oregon immoderate cause candidates it is developing; Blueprint Medicines' quality to make and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO oregon immoderate of its existent and aboriginal cause candidates; Blueprint Medicines' quality to successfully grow its operations, probe level and portfolio of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines' quality to recognize the anticipated benefits of its enforcement enactment modulation plan; and the occurrence of Blueprint Medicines' existent and aboriginal collaborations, financing arrangements, partnerships oregon licensing arrangements. These and different risks and uncertainties are described successful greater item successful the conception entitled "Risk Factors" successful Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' astir caller Annual Report connected Form 10-K, arsenic supplemented by its astir caller Quarterly Report connected Form 10-Q and immoderate different filings that Blueprint Medicines has made oregon whitethorn marque with the SEC successful the future. Any forward-looking statements contained successful this study correspond Blueprint Medicines' views lone arsenic of the day hereof and should not beryllium relied upon arsenic representing its views arsenic of immoderate consequent date. Except arsenic required by law, Blueprint Medicines explicitly disclaims immoderate work to update immoderate forward-looking statements.

Trademarks
Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.